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Abstract	
Atopic	eczema	is	an	itchy	inflammatory	skin	disease	with	a	chronic	relapsing-
remitting	course;	it	has	increased	in	prevalence	in	recent	decades	and	now	affects	
up	to	25%	of	school-aged	children	in	the	developed	world	and	up	to	3%	of	adults.	
Recent	advances	in	understanding	the	aetiology	of	eczema	have	focussed	interest	on	
skin	barrier	dysfunction	as	a	common	precursor	and	pathological	feature.	In	
addition,	genetically	determined	skin	barrier	dysfunction	(associated	with	mutations	
in	the	gene	encoding	filaggrin)	predispose	to	multiple	systemic	atopic	diseases.	First-
line	treatments	for	atopic	eczema	focus	on	maintaining	and	repairing	the	skin	barrier	
(emollients)	and	reducing	inflammation	(topical	steroids);	allergen	and	irritant	
avoidance	are	also	important	to	achieve	disease	control.	Second	and	third-line	
treatments	include	topical	calcineurin	inhibitors,	ultraviolet	light	and	systemic	
immunosuppressant	therapies	of	which	only	ciclosporin	is	licenced	for	the	treatment	
of	atopic	eczema	in	adults.	Novel	biological	therapies	are	in	phase	II-III	clinical	trials.							
	
	
Key	points	
• Atopic	eczema	(synonymous	with	atopic	dermatitis	and	eczema)	is	an	itchy	
inflammatory	skin	disease	with	significant	impact	on	quality	of	life	
• Skin	barrier	dysfunction	in	the	atopic	patient	facilitates	allergen	and	irritant	
penetration	leading	to	skin	and	systemic	inflammation,	including	eczema,	
atopic	asthma,	allergic	rhinitis	and	peanut	allergy	
• The	diagnosis	of	atopic	eczema	is	based	on	clinical	history	and	examination	
• Treatments	for	eczema	include	allergen	and	irritant	avoidance,	emollients,	
topical	steroids,	calcineurin	inhibitors,	ultraviolet	radiation	and	systemic	anti-
inflammatory	agents,	plus	the	treatment	of	secondary	infection	when	
present	
• Urgent	and	emergency	presentations	of	eczema	are	often	associated	with	
secondary	infections	including	Staphylococcus	aureus	and	herpes	simplex	
virus	(as	eczema	herpeticum)	
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Importance	of	eczema	and	its	co-morbidities	
Atopic	eczema	(synonymous	with	atopic	dermatitis	and	eczema1)	is	an	itchy	
inflammatory	skin	disease	which	follows	a	chronic	relapsing	and	remitting	course.	
Moderate-severe	eczema	(Figure	1)	has	a	significant	impact	on	the	quality	of	life	of	
affected	patients	and	their	close	family	because	of	itching,	scratching	and	sleep	
deprivation;	the	impairment	in	quality	of	life	is	of	a	similar	magnitude	to	epilepsy	or	
type	1	diabetes	in	childhood.2	In	approximately	40%	of	cases	eczema	persists	into	
adulthood	(Figure	2),	having	an	impact	on	work	productivity	and	social	functioning.3		
Eczema	is	a	complex	trait,	resulting	from	the	interaction	of	multiple	genetic	and	
multiple	environmental	factors.	Familial	clustering	and	twin	studies	demonstrate	
that	the	disease	is	highly	heritable,	emphasising	the	strong	role	of	genetic	
predisposition4	whilst	the	rapid	rise	in	prevalence	of	eczema	in	the	developed	world	
emphasises	the	importance	of	environmental	factors.	
Up	to	40%	of	eczema	cases	have	atopic	co-morbidities	including	asthma,	allergic	
rhinitis	and	type	1	hypersensitivity	to	food,	which	may	be	initiated	by	
transcutaneous	sensitisation.5	These	co-morbidities	add	substantially	to	the	disease	
burden.	The	chronic	sleep	disturbance	resulting	from	nocturnal	pruritus	in	eczema	
can	lead	to	neurocognitive	impairment.	An	association	with	neurodevelopmental	
disorders,	including	attention	deficit	hyperactivity	disorder,	has	also	been	observed	
from	epidemiological	studies.6			
Diagnostic	criteria	
Eczema	is	diagnosed	on	the	basis	of	clinical	features:	ill-defined,	erythematous,	scaly	
and	pruritic	lesions	with	a	clinical	history	characterised	by	childhood	onset,	flexural	
inflammation	(although	non-flexural	sites	are	usually	involved	in	early	infancy),	a	
background	of	generalised	skin	dryness	(xerosis	and/or	ichthyosis	vulgaris)	and	
associated	atopic	disease	in	the	patient	and/or	first	degree	relatives.3	Eczema	can	
occur	at	any	body	site	but	in	atopic	patients	the	skin	as	a	whole	organ	shows	
impairment	in	barrier	function	and	a	predisposition	to	inflammation,	even	in	
clinically	un-inflamed	sites.	Barrier	dysfunction	also	manifests	as	skin	dryness	(in	part	
because	of	increased	water-loss)	and	susceptibility	to	viral	and	bacterial	infections.	
Principles	of	managing	atopic	eczema	
The	main	principles	of	eczema	management	are	allergen	and	irritant	avoidance,	
emollient	use	and	topical	or	systemic	anti-inflammatory	treatment	(Figure	3).	The	
most	common	allergens	leading	to	sensitisation	in	childhood	are	house	dust	mite,	
grass	pollen,	milk,	egg	and	peanut.	Allergens	inducing	a	type	1	hypersensitivity	
reaction	should	clearly	be	avoided	and	there	is	some	evidence	that	reducing	dust	
mite	exposure	in	the	subset	of	sensitised	patients	improves	eczema	control.7	The	
most	common	irritants	encountered	in	every-day	life	are	soap	and	detergents;	
clinical	experience	demonstrates	the	utility	of	soap	substitutes	(emollients)	when	
bathing,	but	clinical	trial	data	for	this	relatively	inexpensive	intervention	is	currently	
lacking.8	Topical	corticosteroids	should	be	applied	to	areas	of	active	eczema	at	a	
potency	aimed	to	induce	remission,	and	a	steroid	of	lower	potency	or	less	frequent	
application	used	to	maintain	remission.3	Topical	steroids	should	not	be	applied	at	
the	same	time	as	emollients	and	some	specialists	recommend	application	after	
bathing	to	optimise	penetration	through	the	stratum	corneum.	
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Second-	and	third-line	treatments	include	topical	calcineurin	inhibitors	
(pimecrolimus	and	tacrolimus),	ultraviolet	radiation	(principally	narrow	band	UVB	
phototherapy),	oral	corticosteroids	and	the	systemic	immunosuppressants	
ciclosporin,	azathioprine,	methotrexate	and	mycophenolate	mofetil.	However	only	
ciclosporin	is	currently	licensed	in	the	UK	for	adults;	systemic	treatment	in	children	is	
currently	off-licence	but	ciclosporin,	azathioprine	and	methotrexate	are	each	used	
by	dermatology	specialists	in	the	UK	and	internationally.9,	10		
Secondary	infection	with	bacteria	(most	frequently	S	aureus)	is	very	commonly	
associated	with	eczema	exacerbations	and	should	be	treated	concomitantly.	Eczema	
herpeticum	is	an	infection	of	herpes	simplex	virus	within	areas	of	skin	affected	by	
eczema;	it	may	present	as	a	medical	emergency	(see	below).		
A	recent	analysis	of	systematic	reviews	has	concluded	that	there	is	a	paucity	of	
evidence	for	complementary	eczema	treatments	and	non-pharmacological	
interventions	such	as	specialist	clothing;	further	well-designed	clinical	trials	are	
needed.11	
Atopic	eczema	in	acute	medicine	
Patients	with	atopic	eczema	may	present	in	the	acute	setting	with	exacerbations	of	
their	co-morbidities	including	asthma	or	anaphylaxis.	Acute	exacerbations	of	eczema	
(so-called	‘flare-ups’)	are	often	associated	with	S	aureus	infection.	Whether	this	is	
cause	or	effect	is	uncertain,12	but	eczema	control	requires	treatment	of	the	
infection,	(usually	with	a	short	course	of	oral	flucloxacillin)	in	parallel	with	treatment	
of	the	atopic	inflammation.3		
Herpes	simplex	virus	produces	a	severe	and	potentially	life-threatening	infection	of	
eczematous	skin,	described	as	eczema	herpeticum.	This	condition	presents	clinically	
with	eczema	flare,	pain,	systemic	upset	and	characteristic	monomorphic	vesicular	
and	punched-out	lesions.	It	warrants	urgent	referral	to	a	dermatology	specialist	for	
assessment	and	prompt	intervention	with	systemic	antiviral	therapy	(acyclovir	or	
valaciclovir),	which	may	need	to	be	given	parentally,	with	anti-staphylococcal	
therapy	if	indicated.	Periorbital	involvement	necessitates	ophthalmological	review	
because	of	the	risk	of	corneal	ulceration.	Supportive	treatment	including	hospital	
admission,	intravenous	fluid	replacement	and	careful	monitoring	may	be	required	in	
extensive	eczema	herpeticum,	particularly	if	the	patient	is	immunosuppressed	since	
in	this	group	of	patients	mortality	may	be	as	high	as	10%.	
Widespread	dermatitis	can	contribute	to	the	morbidity	and	mortality	of	multi-organ	
failure	therefore	when	present	it	should	be	treated	actively.	The	differential	
diagnosis	in	this	context	includes	atopic	dermatitis,	irritant	or	allergic	contact	
dermatitis,	stasis	dermatitis	and	scabies	infestation.	
Advances	in	understanding	the	aetiology	and	pathogenesis	of	eczema	
The	discovery	in	2006	of	loss-of-function	mutations	in	FLG,	the	gene	encoding	a	skin	
barrier	protein	filaggrin13	and	their	role	in	eczema	predisposition14	led	to	a	paradigm	
shift	in	understanding	the	pathogenesis	of	atopic	eczema.5	This	basic	scientific	
discovery	has	illustrated	the	underlying	role	of	skin	barrier	dysfunction	in	the	
development	of	skin	and	systemic	atopic	diseases.4	A	genetically-determined	
filaggrin	deficiency	in	the	skin	significantly	increases	risk	of	each	disease	in	the	so-
called	‘atopic	march’,	including	eczema,	atopic	asthma,	allergic	rhinitis	and	peanut	
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allergy.4,	15	Skin	barrier	dysfunction	may	be	quantified	in	part	by	trans-epidermal	
water	loss	(TEWL)	and	increased	TEWL	is	present	as	a	precursor	to	eczema	in	early	
infancy.16	Building	on	this	observation,	recent	clinical	trials	have	produced	evidence	
to	suggest	that	intensive	emollient	use	from	soon	after	birth,	aimed	to	enhance	the	
skin	barrier,	reduces	the	incidence	of	eczema	by	~50%	in	high	risk	infants	(defined	as	
those	with	a	first	degree	relative	having	atopic	disease).17	However,	the	authors	
emphasise	that	larger	trials	are	required	before	this	approach	can	be	recommended	
for	routine	clinical	practice.	
Despite	these	major	advances	in	understanding	eczema	pathogenesis,	there	remain	
considerable	gaps	in	knowledge.	More	than	30	genetic	risk	loci	have	now	been	
identified	by	genome-wide	association	studies	in	atopic	eczema	but	the	majority	of	
these	are	in	intergenic	regions	with	unknown	function.	Eczema	currently	lags	behind	
psoriasis	and	other	systemic	inflammatory	diseases	in	the	availability	of	biological	
therapies.	However,	the	results	of	a	phase	II	clinical	trial	investigating	dupilumab	(a	
human	monoclonal	antibody	against	interleukin-4	and	interleukin-13)	in	adults	with	
moderate-severe	atopic	eczema	are	promising:	85%	of	patients	in	the	dupilumab	
group,	as	compared	with	35%	of	those	in	the	placebo	group,	had	a	50%	reduction	in	
the	eczema	severity	score	(P<0.001)	after	12	weeks	of	monotherapy.18	A	Phase	IIb	
trial	has	shown	a	dose-dependent	improvement	in	adults	with	moderate-to-severe	
atopic	eczema;19	there	were	no	significant	safety	concerns	reported,	although	there	
was	an	increased	incidence	of	cutaneous	herpes	virus	infections	in	the	dupilumab-
treated	group,	a	risk	which	will	require	further	assessment.	
Another	area	of	intensive	research	interest	is	the	complex	interaction	of	skin	and	gut	
microbiome	with	cutaneous	inflammation.12	These	studies	which	have	been	made	
possible	by	modern	sequencing	technologies	to	circumvent	the	need	for	selective	
bacterial	cultures.20	The	approach	has	illustrated	a	reduction	in	microbial	diversity	in	
active	eczema	in	addition	to	the	well-established	over-growth	of	S	aureus.12		
Conclusions	and	future	prospects	
In	conclusion,	atopic	eczema	represents	a	complex	and	challenging	disorder	for	both	
patient	and	physician.	Simple	interventions	including	the	avoidance	of	allergens	and	
irritants,	combined	with	emollient	use	and	topical	corticosteroids,	provide	the	
mainstay	of	treatment	and	are	effective	in	the	majority	of	cases.	A	subset	of	severe	
recalcitrant	disease	necessitates	systemic	immunosuppression	but	more	targeted	
and	effective	therapies	are	urgently	required.	Recent	advances	in	understanding	
both	genetic	and	environmental	factors	in	eczema	pathogenesis	offer	the	
opportunity	for	significant	progress	in	this	regard.	The	diverse	range	of	phenotypes	
observed	within	the	clinical	diagnosis	of	‘eczema’	illustrates	the	need	for	a	
personalised	medicine	approach,	to	target	novel	therapies	to	subsets	of	patients	
whose	disease	is	driven	by	specific	pathways.	The	emerging	knowledge	of	tissue	
microbial	diversity	and	its	role	in	modulating	inflammatory	disease	also	offers	
opportunity	for	therapeutic	manipulation	of	microbial	communities	in	the	future.20	
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Figure	1.	Child	with	moderate-severe	atopic	eczema		
The	child’s	upper	limb	shows	multiple	areas	of	eczematous	
inflammation	in	flexural	and	non-flexural	sites,	on	a	background	of		
generalised	ichthyosis	vulgaris	(common	dry,	scaly	skin).	
	
	
	
	
	
	
	
	
	
Figure	2.	Adult	severe	atopic	eczema		
	 	 	 	 	 	 The	skin	on	this	adult’s	upper	back	shows		
	 	 	 	 	 	 widespread	erythema	and	scaling,	indicative		
of	active	eczema,	with	multiple	
excoriations.	
	
	
	
	
	
	
Figure	3.	Principles	of	treatment	for	atopic	eczema	
	
